<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697034</url>
  </required_header>
  <id_info>
    <org_study_id>05-467</org_study_id>
    <nct_id>NCT00697034</nct_id>
  </id_info>
  <brief_title>Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin</brief_title>
  <official_title>Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to examine the role of nerves in the skin in psoriasis&#xD;
      and to better understand the effects of capsaicin in psoriasis.In this study, capsaicin will&#xD;
      be compared to a moisturizer (aquaphor ointment).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of qualified and willing volunteers.&#xD;
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of capsaicin on small nerve fiber function in psoriasis</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will be patients with chronic plaque-type psoriasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women who are 18 years of age or older.&#xD;
&#xD;
          -  Diagnosis of plaque-type psoriasis is required to be confirmed by clinical criteria.&#xD;
&#xD;
          -  Subjects must be in general good health with no other skin disease, disease state or&#xD;
             physical condition which would impair evaluation of psoriasis or which would increase&#xD;
             their health risk by study participation.&#xD;
&#xD;
          -  Subjects must be willing to receive topical capsaicin weekly for 6 weeks and must be&#xD;
             willing to undergo 3mm punch biopsies at baseline and at week 6.&#xD;
&#xD;
          -  Subjects may not receive any systemic therapies during the study.&#xD;
&#xD;
          -  Subjects are required to complete a 4 week washout period from any systemic medication&#xD;
             and/or phototherapy prior to enrolling in the study.&#xD;
&#xD;
          -  Stable use of moisturizers will be allowed provided that use has been stable for at&#xD;
             least 14 days.&#xD;
&#xD;
          -  Women of child bearing age will be required to have a negative pregnancy test in order&#xD;
             to enroll in the study and will be required to maintain adequate birth control&#xD;
             throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are unable to complete the required measures.&#xD;
&#xD;
          -  Subjects diagnosed with other skin diseases that would affect the measurement of&#xD;
             cutaneous blood flow.&#xD;
&#xD;
          -  Subjects with any history of any disease associated with neuropathy, including&#xD;
             diabetes, alcoholism, uremia, HIV infection, hypothyroidism, or cancer chemotherapy.&#xD;
&#xD;
          -  Subjects who are currently enrolled in any investigational study in which the subject&#xD;
             is receiving any type of drug, biologic, or non-drug therapy and subjects undergoing&#xD;
             treatment with another investigational drug or approved therapy for investigational&#xD;
             use within 28 days prior to investigational drug administration.&#xD;
&#xD;
          -  Subjects who have used any topical therapy for psoriasis or other skin diseases in the&#xD;
             past 7 days.&#xD;
&#xD;
          -  Subjects receiving any of the following treatments or agents within the 28 days prior&#xD;
             to investigational drug administration will be excluded: systemic retinoids, systemic&#xD;
             steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept,&#xD;
             efalizumab, infliximab, adalimumab or mofetil or other systemic immunosuppressant, and&#xD;
             phototherapy, including Ultraviolet B (UVB) and Psoralen + Ultraviolet A (PUVA).&#xD;
&#xD;
          -  Subjects with a known allergy to capsaicin.&#xD;
&#xD;
          -  Children less than 18 years of age.&#xD;
&#xD;
          -  Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Yosipovitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

